These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31707187)

  • 1. Bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in an infant.
    Gates C; Tomboc P; Allison A; Carr M
    Int J Pediatr Otorhinolaryngol; 2020 Feb; 129():109762. PubMed ID: 31707187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic bevacizumab for recurrent respiratory papillomatosis.
    Baday YI; Ongkasuwan J; Venkatramani R
    Int J Pediatr Otorhinolaryngol; 2020 Nov; 138():110352. PubMed ID: 32906078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children.
    Carnevale C; Ferrán-De la Cierva L; Til-Pérez G; Peña-Zarza JA; Osona-Rodriguez B; Martinez-Lozano J; Sarría-Echegaray P; Arancibia-Tagle D; Tomás-Barberán M
    Laryngoscope; 2019 Apr; 129(4):1001-1004. PubMed ID: 30588638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children.
    Rogers DJ; Ojha S; Maurer R; Hartnick CJ
    JAMA Otolaryngol Head Neck Surg; 2013 May; 139(5):496-501. PubMed ID: 23681032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Follow-Up on Systemic Bevacizumab Treatment in Recurrent Respiratory Papillomatosis.
    Evers G; Schliemann C; Beule A; Schmidt LH; Schulze AB; Kessler C; Hoffmann TK; Wiewrodt R; Groll AH; Bleckmann A; Rudack C; Berdel WE; Mohr M
    Laryngoscope; 2021 Jun; 131(6):E1926-E1933. PubMed ID: 33382105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
    Bedoya A; Glisinski K; Clarke J; Lind RN; Buckley CE; Shofer S
    Am J Case Rep; 2017 Jul; 18():842-846. PubMed ID: 28757601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature.
    Jackowska J; Piersiala K; Klimza H; Wierzbicka M
    Otolaryngol Pol; 2018 Jun; 72(4):1-8. PubMed ID: 30190442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
    Best SR; Mohr M; Zur KB
    Laryngoscope; 2017 Oct; 127(10):2225-2229. PubMed ID: 28657692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up.
    Ruiz R; Balamuth N; Javia LR; Zur KB
    Laryngoscope; 2022 Oct; 132(10):2071-2075. PubMed ID: 35043981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review.
    Pogoda L; Ziylan F; Smeeing DPJ; Dikkers FG; Rinkel RNPM
    Eur Arch Otorhinolaryngol; 2022 Sep; 279(9):4229-4240. PubMed ID: 35462578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis.
    Sidell DR; Nassar M; Cotton RT; Zeitels SM; de Alarcon A
    Ann Otol Rhinol Laryngol; 2014 Mar; 123(3):214-21. PubMed ID: 24633948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery and Adjuvant Therapy Improve Derkay Scores in Adult and Pediatric Respiratory Papillomatosis.
    Hock K; Kennedy A; Howell R; Friedman A; de Alarcon A; Khosla S
    Laryngoscope; 2022 Dec; 132(12):2420-2426. PubMed ID: 35119691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis.
    Ballestas SA; Hidalgo Lopez J; Klein AM; Steuer C; Shin DM; Abousaud M; Schmitt NC; Teng Y; Saba NF; Tkaczuk AT
    Laryngoscope; 2023 Oct; 133(10):2725-2733. PubMed ID: 36815602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population.
    Tkaczuk A; Trivedi S; Mody MD; Steuer CE; Shin DM; Klein AM; Saba NF
    Laryngoscope; 2021 Mar; 131(3):E921-E928. PubMed ID: 33107615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis.
    Best SR; Friedman AD; Landau-Zemer T; Barbu AM; Burns JA; Freeman MW; Halvorsen YD; Hillman RE; Zeitels SM
    Ann Otol Rhinol Laryngol; 2012 Sep; 121(9):587-93. PubMed ID: 23012897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
    So RJ; Rayle C; Joo HH; Huang EY; Seiwert TY; Raabe EH; Best SR
    Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laryngotracheal Recurrent Papillomatosis: A Case Study and Survey of Surgical and Systemic Management.
    Borrelli M; Nasrollahi T; Raskin J; Khan S; Alexander RE
    Ear Nose Throat J; 2022 Dec; 101(10_suppl):47S-51S. PubMed ID: 36173000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.
    Collette F; Lawson G; Hassid S; Delahaut G; Bachy V; Van Der Vorst S; Faugeras L; Gilliaux Q; D'Hondt L
    Head Neck; 2023 May; 45(5):1071-1079. PubMed ID: 36840929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report.
    Hamdi O; Dome J; Zalzal G; Preciado D
    Int J Pediatr Otorhinolaryngol; 2020 Jan; 128():109706. PubMed ID: 31610441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.
    Sidell DR; Balakrishnan K; Best SR; Zur K; Buckingham J; De Alarcon A; Baroody FM; Bock JM; Boss EF; Bower CM; Campisi P; Chen SF; Clarke JM; Clarke KD; Cocciaglia A; Cotton RT; Cuestas G; Davis KL; DeFago VH; Dikkers FG; Dossans I; Florez W; Fox E; Friedman AD; Grant N; Hamdi O; Hogikyan ND; Johnson K; Johnson LB; Johnson RF; Kelly P; Klein AM; Lawlor CM; Leboulanger N; Levy AG; Lam D; Licameli GR; Long S; Lott DG; Manrique D; McMurray JS; Meister KD; Messner AH; Mohr M; Mudd P; Mortelliti AJ; Novakovic D; Ongkasuwan J; Peer S; Piersiala K; Prager JD; Pransky SM; Preciado D; Raynor T; Rinkel RNPM; Rodriguez H; Rodríguez VP; Russell J; Scatolini ML; Scheffler P; Smith DF; Smith LP; Smith ME; Smith RJH; Sorom A; Steinberg A; Stith JA; Thompson D; Thompson JW; Varela P; White DR; Wineland AM; Yang CJ; Zdanski CJ; Derkay CS
    Laryngoscope; 2021 Jun; 131(6):E1941-E1949. PubMed ID: 33405268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.